Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small-cell lung cancer and interstitial lung disease

Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small-cell lung cancer and interstitial lung disease - Rechallenge chemotherapy with CBDCA+PTX/nab-PTX for patients with NSCLC and ILD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050630

Enrollment

Registered

2023-03-20

Start date

2023-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-small-cell lung cancer and interstitial lung disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically or cytologically proven NSCLC 2) Unresectable advanced or recurrent NSCLC 3) Patients with interstitial lung disease diagnosed by computed tomography before the first line of chemotherapy 4) Patients who had received CBDCA+PTX/nab-PTX as a first-line chemotherapy 5) Patients who had received CBDCA+PTX/nab-PTX rechallenge in late line chemotherapy between January 2018 and December 2022.

Exclusion criteria

Exclusion criteria: Disagree to study registration

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
Overall survival, Progression-free survival, Disease control rate, Safety	—

Countries

Japan

Contacts

Public ContactTaku Itoh

Chiba University Hospital Department of Respiratory medicine

titoh@chiba-u.jp043-222-7171

Outcome results